Tags

Type your tag names separated by a space and hit enter

[Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia].
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 16; 43(0):E014.ZJ

Abstract

The novel coronavirus 2019 (COVID-19) infected patients by binding human ACE2, leading to severe pneumonia and highly mortality rate in patients. At present, there is no definite and effective treatment for COVID-19. ACE2 plays an important role in the RAS, and the imbalance between ACE/Ang II/AT1R pathway and ACE2/Ang (1-7)/Mas receptor pathway in the RAS system will lead to multi-system inflammation. Increased ACE and Ang II are poor prognostic factors for severe pneumonia. Animal studies have shown that RAS inhibitors could effectively relieve symptoms of acute severe pneumonia and respiratory failure. The binding of COVID-19 and ACE2 resulted in the exhaustion of ACE2, and then ACE2/Ang (1-7)/Mas receptor pathway was inhibited. The balance of the RAS system was broken, and this would lead to the exacerbation of acute severe pneumonia. Therefore, we speculate that ACEI and AT1R inhibitors could be used in patients with COVID-19 pneumonia under the condition of controlling blood pressure, and might reduce the pulmonary inflammatory response and mortality.

Authors+Show Affiliations

Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan 250013, China.The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese Ministry of Health and Chinese Academy of Medical Sciences, Department of Cardiology, Qilu Hospital of Shandong University, Jinan 250012, China.Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan 250013, China.Department of Cardiology, Jinan Central Hospital Affiliated to Shandong University, Jinan 250013, China.

Pub Type(s)

English Abstract
Journal Article

Language

chi

PubMed ID

32061198

Citation

Sun, M L., et al. "[Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia]." Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases, vol. 43, no. 0, 2020, pp. E014.
Sun ML, Yang JM, Sun YP, et al. [Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(0):E014.
Sun, M. L., Yang, J. M., Sun, Y. P., & Su, G. H. (2020). [Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases, 43(0), E014. https://doi.org/10.3760/cma.j.issn.1001-0939.2020.0014
Sun ML, et al. [Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 16;43(0):E014. PubMed PMID: 32061198.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia]. AU - Sun,M L, AU - Yang,J M, AU - Sun,Y P, AU - Su,G H, Y1 - 2020/02/16/ PY - 2020/2/16/entrez PY - 2020/2/16/pubmed PY - 2020/2/16/medline SP - E014 EP - E014 JF - Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases JO - Zhonghua Jie He He Hu Xi Za Zhi VL - 43 IS - 0 N2 - The novel coronavirus 2019 (COVID-19) infected patients by binding human ACE2, leading to severe pneumonia and highly mortality rate in patients. At present, there is no definite and effective treatment for COVID-19. ACE2 plays an important role in the RAS, and the imbalance between ACE/Ang II/AT1R pathway and ACE2/Ang (1-7)/Mas receptor pathway in the RAS system will lead to multi-system inflammation. Increased ACE and Ang II are poor prognostic factors for severe pneumonia. Animal studies have shown that RAS inhibitors could effectively relieve symptoms of acute severe pneumonia and respiratory failure. The binding of COVID-19 and ACE2 resulted in the exhaustion of ACE2, and then ACE2/Ang (1-7)/Mas receptor pathway was inhibited. The balance of the RAS system was broken, and this would lead to the exacerbation of acute severe pneumonia. Therefore, we speculate that ACEI and AT1R inhibitors could be used in patients with COVID-19 pneumonia under the condition of controlling blood pressure, and might reduce the pulmonary inflammatory response and mortality. SN - 1001-0939 UR - https://www.unboundmedicine.com/medline/citation/32061198/full_citation L2 - http://journal.yiigle.com/LinkIn.do?linkin_type=pubmed&DOI=10.3760/cma.j.issn.1001-0939.2020.0014 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.